Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Cash & Equivalents · Q4 FY2025 · quarter ended Dec 2025
Cash & equivalents falls 34.0% from a year ago
Cash & equivalents stood at $7.77M at the end of Q4 FY2025, down 34.0% from a year earlier. Over 3 fiscal years it compounded at +3.0% a year.
Context
- Cash & equivalents amounted to 25.7% of total assets at the end of Q4 FY2025, down 36.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -34.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.77M USD
- Year-over-year change
- -34.0%
- 4-year CAGR
- +16.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.77M | -34.0% |
| FY2024 | 2024-12-31 | 11.76M | +21.4% |
| FY2023 | 2023-12-31 | 9.69M | +36.4% |
| FY2022 | 2022-12-31 | 7.1M | +69.9% |
| FY2021 | 2021-12-31 | 4.18M | — |
Cash & Equivalents vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -34.0% is the 8th highest of 10, against a peer median of +5.7%.
- Cash & equivalents amounts to 25.7% of total assets for NNNN, versus a peer median of 20.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $712M USD | +65.2% | +30.1% | 5.4% | |
| Mar 2026 | $466.01M USD | +79.2% | +1.5% | 87.6% | |
| Mar 2026 | CA$233.36M CAD | +5.7% | -0.8% | 17.8% | |
| Dec 2025 | $229.34M USD | — | — | 68.4% | |
| Mar 2026 | $65.6M USD | -32.4% | -11.1% | 6.2% | |
| Mar 2026 | $41.03M USD | +41.4% | -30.4% | 31.8% | |
| Feb 2026 | $37.81M USD | -15.5% | +24.7% | 14.5% | |
| Mar 2026 | $35.59M USD | +187.3% | +18.5% | 38.1% | |
| Mar 2026 | $31.41M USD | -47.7% | -35.4% | 23.1% | |
| Mar 2026 | $24.41M USD | -46.6% | +18.4% | 4.8% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $7.77M USD | -34.0% | +3.0% | 25.7% |
| Peer median (excluding NNNN) | — | +5.7% | +1.5% | 20.4% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.